Brokerages Set GSK plc (LON:GSK) PT at GBX 2,034.29

GSK plc (LON:GSK) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is GBX 2,034.29.

Several equities research analysts have recently weighed in on GSK shares. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Thursday, March 26th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup lowered their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research note on Thursday, May 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a research note on Wednesday, May 27th.

GSK Stock Performance

GSK opened at GBX 1,873 on Thursday. The stock has a market cap of £74.77 billion, a PE ratio of 13.18, a P/E/G ratio of 1.24 and a beta of 0.30. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The stock’s 50 day simple moving average is GBX 1,994.96 and its 200-day simple moving average is GBX 1,952.97.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The company had revenue of GBX 762.90 billion for the quarter. Sell-side analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Transactions at GSK

In other news, insider Jonathan Symonds acquired 5,000 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was bought at an average price of GBX 1,951 per share, with a total value of £97,550. Also, insider Anne Beal purchased 196 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Over the last 90 days, insiders bought 9,619 shares of company stock valued at $19,452,794. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.